These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 7609678)

  • 1. Excess catecholamines and the metabolic syndrome: should central imidazoline receptors be a therapeutic target?
    Rupp H; Jacob R
    Med Hypotheses; 1995 Mar; 44(3):217-25. PubMed ID: 7609678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Central imidazoline- and alpha 2-receptors involved in the cardiovascular actions of centrally acting antihypertensive agents.
    Head GA
    Ann N Y Acad Sci; 1999 Jun; 881():279-86. PubMed ID: 10415926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Why imidazoline receptor modulator in the treatment of hypertension?
    Schäfer SG; Kaan EC; Christen MO; Löw-Kröger A; Mest HJ; Molderings GJ
    Ann N Y Acad Sci; 1995 Jul; 763():659-72. PubMed ID: 7677385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel mechanism of action for hypertension control: moxonidine as a selective I1-imidazoline agonist.
    Ernsberger P; Haxhiu MA; Graff LM; Collins LA; Dreshaj I; Grove DL; Graves ME; Schäfer SG; Christen MO
    Cardiovasc Drugs Ther; 1994 Mar; 8 Suppl 1():27-41. PubMed ID: 8068578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The imidazoline receptor in control of blood pressure by clonidine and allied drugs.
    Reis DJ; Piletz JE
    Am J Physiol; 1997 Nov; 273(5):R1569-71. PubMed ID: 9374795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Central imidazoline receptors and centrally acting anti-hypertensive agents.
    Head GA; Burke SL; Chan CK
    Clin Exp Hypertens; 1997; 19(5-6):591-605. PubMed ID: 9247741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of the receptor involved in the central hypotensive effect of rilmenidine and moxonidine.
    Bock C; Niederhoffer N; Szabo B
    Naunyn Schmiedebergs Arch Pharmacol; 1999 Apr; 359(4):262-71. PubMed ID: 10344524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. I1 imidazoline agonists. General clinical pharmacology of imidazoline receptors: implications for the treatment of the elderly.
    Prichard BN; Graham BR
    Drugs Aging; 2000 Aug; 17(2):133-59. PubMed ID: 10984201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacology and clinical use of moxonidine, a new centrally acting sympatholytic antihypertensive agent.
    Prichard BN; Owens CW; Graham BR
    J Hum Hypertens; 1997 Aug; 11 Suppl 1():S29-45. PubMed ID: 9321737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative importance of medullary brain nuclei for the sympatho-inhibitory actions of rilmenidine in the anaesthetized rabbit.
    Head GA; Burke SL
    J Hypertens; 1998 Apr; 16(4):503-17. PubMed ID: 9797196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Central imidazoline (I1) receptors as targets of centrally acting antihypertensives: moxonidine and rilmenidine.
    van Zwieten PA
    J Hypertens; 1997 Feb; 15(2):117-25. PubMed ID: 9469786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Importance of imidazoline receptors in the cardiovascular actions of centrally acting antihypertensive agents.
    Head GA
    Ann N Y Acad Sci; 1995 Jul; 763():531-40. PubMed ID: 7677371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Site-dependent inhibition of neuronal c-jun in the brainstem elicited by imidazoline I1 receptor activation: role in rilmenidine-evoked hypotension.
    Wang X; Li G; Abdel-Rahman AA
    Eur J Pharmacol; 2005 May; 514(2-3):191-9. PubMed ID: 15910806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical pharmacology of drugs acting on imidazoline and adrenergic receptors. Studies with clonidine, moxonidine, rilmenidine, and atenolol.
    Reid JL; Panfilov V; MacPhee G; Elliott HL
    Ann N Y Acad Sci; 1995 Jul; 763():673-8. PubMed ID: 7677387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective antihypertensive action of moxonidine is mediated mainly by I1-imidazoline receptors in the rostral ventrolateral medulla.
    Haxhiu MA; Dreshaj I; Schäfer SG; Ernsberger P
    J Cardiovasc Pharmacol; 1994; 24 Suppl 1():S1-8. PubMed ID: 7533221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. From alpha and beta to I1: an overview of sympathetic receptors involved in blood pressure control targets for drug treatment.
    van Zwieten PA
    J Cardiovasc Pharmacol; 1996; 27 Suppl 3():S5-10. PubMed ID: 8872294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The I1-imidazoline receptor: from binding site to therapeutic target in cardiovascular disease.
    Ernsberger P; Friedman JE; Koletsky RJ
    J Hypertens Suppl; 1997 Jan; 15(1):S9-23. PubMed ID: 9050981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Historic aspects in the identification of the I1 receptor and the pharmacology of imidazolines.
    Dominiak P
    Cardiovasc Drugs Ther; 1994 Mar; 8 Suppl 1():21-6. PubMed ID: 8068577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism of the sympathoinhibition produced by the clonidine-like drugs rilmenidine and moxonidine.
    Szabo B; Bock C; Nordheim U; Niederhoffer N
    Ann N Y Acad Sci; 1999 Jun; 881():253-64. PubMed ID: 10415923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between imidazoline and alpha2-adrenoceptors involved in the sympatho-inhibitory actions of centrally acting antihypertensive agents.
    Head GA; Chan CK; Burke SL
    J Auton Nerv Syst; 1998 Oct; 72(2-3):163-9. PubMed ID: 9851565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.